Literature DB >> 30342588

Biomarkers in Chronic Rhinosinusitis with Nasal Polyps.

Alan D Workman1, Michael A Kohanski1, Noam A Cohen2.   

Abstract

Chronic rhinosinusitis is a complex disease that exists along the inflammatory spectrum between types 1 and 2 inflammation. The classic phenotypic differentiation of chronic rhinosinusitis based on the presence or absence of inflammatory polyps remains one of the best differentiators of response to therapy. Development of biologics for the treatment of atopic disease and asthma and topical therapies for sinusitis have placed renewed emphasis on understanding the pathophysiology of polyp disease. Identification of key markers of polyposis will allow for better stratification of inflammatory polyp disease endotypes to objectively identify medical therapies and track response to treatment. Published by Elsevier Inc.

Entities:  

Keywords:  Biomarkers; Chronic rhinosinusitis; Genetics; Microbiome; Polyps

Mesh:

Substances:

Year:  2018        PMID: 30342588      PMCID: PMC6201304          DOI: 10.1016/j.iac.2018.06.006

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  80 in total

1.  Interleukin-25 and interleukin-33 as mediators of eosinophilic inflammation in chronic rhinosinusitis.

Authors:  Matthew Lam; Laura Hull; Andrew Imrie; Kornkiat Snidvongs; David Chin; Ellie Pratt; Larry Kalish; Raymond Sacks; Peter Earls; William Sewell; Richard J Harvey
Journal:  Am J Rhinol Allergy       Date:  2015 May-Jun       Impact factor: 2.467

2.  Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe.

Authors:  D Jarvis; R Newson; J Lotvall; D Hastan; P Tomassen; T Keil; M Gjomarkaj; B Forsberg; M Gunnbjornsdottir; J Minov; G Brozek; S E Dahlen; E Toskala; M L Kowalski; H Olze; P Howarth; U Krämer; J Baelum; C Loureiro; L Kasper; P J Bousquet; J Bousquet; C Bachert; W Fokkens; P Burney
Journal:  Allergy       Date:  2011-11-04       Impact factor: 13.146

3.  EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.

Authors:  Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald
Journal:  Rhinology       Date:  2012-03       Impact factor: 3.681

4.  European Position Paper on Rhinosinusitis and Nasal Polyps 2012.

Authors:  Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald
Journal:  Rhinol Suppl       Date:  2012-03

5.  Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Bruce K Tan; Quan-Zhen Li; Lydia Suh; Atsushi Kato; David B Conley; Rakesh K Chandra; Jinchun Zhou; James Norton; Roderick Carter; Monique Hinchcliff; Kathleen Harris; Anju Peters; Leslie C Grammer; Robert C Kern; Chandra Mohan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2011-10-13       Impact factor: 10.793

6.  Familial risk of chronic rhinosinusitis with and without nasal polyposis: genetics or environment.

Authors:  Gretchen M Oakley; Karen Curtin; Quinn Orb; Carole Schaefer; Richard R Orlandi; Jeremiah A Alt
Journal:  Int Forum Allergy Rhinol       Date:  2015-02-12       Impact factor: 3.858

7.  Reduced expression of antimicrobial PLUNC proteins in nasal polyp tissues of patients with chronic rhinosinusitis.

Authors:  S Seshadri; D C Lin; M Rosati; R G Carter; J E Norton; L Suh; A Kato; R K Chandra; K E Harris; H W Chu; A T Peters; B K Tan; D B Conley; L C Grammer; R C Kern; R P Schleimer
Journal:  Allergy       Date:  2012-07       Impact factor: 13.146

8.  Nitric oxide evaluation in upper and lower respiratory tracts in nasal polyposis.

Authors:  C Delclaux; D Malinvaud; B Chevalier-Bidaud; E Callens; B Mahut; P Bonfils
Journal:  Clin Exp Allergy       Date:  2008-05-08       Impact factor: 5.018

9.  Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.

Authors:  Claus Bachert; Ana R Sousa; Valerie J Lund; Glenis K Scadding; Philippe Gevaert; Shuaib Nasser; Stephen R Durham; Marjolein E Cornet; Harsha H Kariyawasam; Jane Gilbert; Daren Austin; Aoife C Maxwell; Richard P Marshall; Wytske J Fokkens
Journal:  J Allergy Clin Immunol       Date:  2017-07-04       Impact factor: 10.793

10.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Authors:  Nicola A Hanania; Michael Noonan; Jonathan Corren; Phillip Korenblat; Yanan Zheng; Saloumeh K Fischer; Melissa Cheu; Wendy S Putnam; Elaine Murray; Heleen Scheerens; Cecile T J Holweg; Romeo Maciuca; Sarah Gray; Ramona Doyle; Dana McClintock; Julie Olsson; John G Matthews; Karl Yen
Journal:  Thorax       Date:  2015-05-22       Impact factor: 9.139

View more
  22 in total

1.  YAP1 expression in nasal polyps and its relationship with epithelial mesenchymal transition.

Authors:  Jiabin Zhan; Huijuan Zhan; Jing Zheng; Xin Wei; Yihui Fu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  The treatment efficacy of nasal polyposis on olfactory functions, clinical scoring systems and inflammation markers.

Authors:  Zehra Betul Paksoy; Melih Cayonu; Cigdem Yucel; Turan Turhan
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-08-31       Impact factor: 2.503

3.  When rhinosinusitis is not just rhinosinusitis: Clinical characteristics and phenotypes of patients with type 2 chronic rhinosinusitis with nasal polyps.

Authors:  Ignazio La Mantia; Giorgio Ciprandi; Attilio Varricchio; Martina Ragusa; Federica Cipolla; Claudio Andaloro
Journal:  Acta Biomed       Date:  2022-08-31

Review 4.  From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.

Authors:  Ian D Pavord; Elisabeth H Bel; Arnaud Bourdin; Robert Chan; Joseph K Han; Oliver N Keene; Mark C Liu; Neil Martin; Alberto Papi; Florence Roufosse; Jonathan Steinfeld; Michael E Wechsler; Steven W Yancey
Journal:  Allergy       Date:  2021-09-16       Impact factor: 14.710

5.  The diagnostic importance of periostin as a biomarker in chronic rhinosinusitis with nasal polyp.

Authors:  Gamze Ozturk Yilmaz; Erdem Atalay Cetinkaya; Hulya Eyigor; Hamit Yasar Ellidag; Kadir Balaban; Omer Tarik Selcuk; Gokhan Yilmaz; Ozer Erdem Gur
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-06-20       Impact factor: 3.236

Review 6.  Evolving Rhinology: Understanding the Burden of Chronic Rhinosinusitis Today, Tomorrow, and Beyond.

Authors:  Michael T Yim; Richard R Orlandi
Journal:  Curr Allergy Asthma Rep       Date:  2020-02-24       Impact factor: 4.806

7.  LINGO3 regulates mucosal tissue regeneration and promotes TFF2 dependent recovery from colitis.

Authors:  Kelly M Zullo; Bonnie Douglas; Nicole M Maloney; Yingbiao Ji; Yun Wei; Karl Herbine; Rachel Cohen; Christopher Pastore; Zvi Cramer; Xin Wang; Wenjie Wei; Ma Somsouk; Li Yin Hung; Christopher Lengner; Michael H Kohanski; Noam A Cohen; De'Broski R Herbert
Journal:  Scand J Gastroenterol       Date:  2021-05-03       Impact factor: 2.423

8.  Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.

Authors:  Shigeharu Fujieda; Shoji Matsune; Sachio Takeno; Nobuo Ohta; Mikiya Asako; Claus Bachert; Tomoyuki Inoue; Yoshinori Takahashi; Hiroyuki Fujita; Yamo Deniz; Paul Rowe; Benjamin Ortiz; Yongtao Li; Leda P Mannent
Journal:  Allergy       Date:  2021-06-04       Impact factor: 14.710

Review 9.  Novel therapeutic targets for allergic airway disease in children.

Authors:  Alessandro Giallongo; Giuseppe Fabio Parisi; Amelia Licari; Giulio Pulvirenti; Caterina Cuppari; Carmelo Salpietro; Gian Luigi Marseglia; Salvatore Leonardi
Journal:  Drugs Context       Date:  2019-07-09

Review 10.  Tuft cells in the pathogenesis of chronic rhinosinusitis with nasal polyps and asthma.

Authors:  Elizabeth A Sell; Jorge F Ortiz-Carpena; De'Broski R Herbert; Noam A Cohen
Journal:  Ann Allergy Asthma Immunol       Date:  2020-10-26       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.